加拿大可切除 II/III 期非小细胞肺癌管理共识推荐意见：一项改良 Delphi 流程的研究结果。

Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process.

机构信息

Department of Thoracic Surgery, McGill University Health Center, Montreal, QC H3G 1A4, Canada.

Department of Medical Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada.

出版信息

Curr Oncol. 2023 Dec 6;30(12):10363-10384. doi: 10.3390/curroncol30120755.

DOI:10.3390/curroncol30120755

PMID:38132389

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10742991/

Abstract

The treatment paradigm for patients with stage II/III non-small-cell lung cancer (NSCLC) is rapidly evolving. We performed a modified Delphi process culminating at the Early-stage Lung cancer International eXpert Retreat (ELIXR23) meeting held in Montreal, Canada, in June 2023. Participants included medical and radiation oncologists, thoracic surgeons and pathologists from across Quebec. Statements relating to diagnosis and treatment paradigms in the preoperative, operative and postoperative time periods were generated and modified until all held a high level of consensus. These statements are aimed to help guide clinicians involved in the treatment of patients with stage II/III NSCLC.

摘要

对于 II/III 期非小细胞肺癌（NSCLC）患者的治疗模式正在迅速发展。我们进行了一项改良 Delphi 流程，最终在 2023 年 6 月在加拿大蒙特利尔举行的早期肺癌国际专家 retreat（ELIXR23）会议上达成共识。参与者包括来自魁北克各地的医学和放射肿瘤学家、胸外科医生和病理学家。与术前、术中和术后期间的诊断和治疗模式相关的陈述被生成并修改，直到所有陈述都达到高度共识。这些陈述旨在帮助指导参与 II/III 期 NSCLC 患者治疗的临床医生。